EmVenio Research, in partnership with Prime Healthcare, has opened two dedicated clinical research centers in Dallas and Atlanta. These sites, located within Prime Healthcare hospitals, are now available for pre-study visits from clinical research organizations and trial sponsors.
The collaboration seeks to improve patient access to clinical research, particularly within underrepresented communities. According to Thad Wolfram, President of EmVenio, the limited availability of research sites hinders patient participation and impacts study timelines. The new sites aim to address this by reaching new community-based participant populations, allowing for faster enrollment and study completion.
Addressing Healthcare Disparities
EmVenio and Prime Healthcare share a mission to provide quality clinical research among underrepresented populations. They are dedicated to analyzing social determinants of health to identify communities lacking access to care and provide them with access to clinical trials. This initiative also offers hospital physicians the opportunity to engage in clinical research and provide research as a care option to their patients.
Dr. Sunny Bhatia, President and Chief Medical Officer of Prime Healthcare, emphasized that creating access to care is a primary driver for Prime Healthcare's success. This partnership with EmVenio offers a unique opportunity to provide clinical trials as a readily accessible care option to a wider population.
Locations and Future Expansion
The Dallas-area research site is located on the campus of Dallas Medical Center, while the Atlanta-area location is at Southern Regional Medical Center. EmVenio plans to open additional research sites at Prime hospitals in Michigan and Kansas in 2024, with further expansion planned for 2025.
EmVenio also operates independent mobile community research sites in both cities. The partnership with Prime Healthcare aims to provide added convenience and access to diverse communities, challenging the traditional clinical trial model that often results in skewed research findings not reflective of the whole population's demographic makeup.
